The honeymoon is officially over. Reports are flying that President Trump has signed off on a plan to dump FDA Commissioner Dr. Marty Makary, and honestly, it’s not just about one bad policy or a single headline. It’s a total breakdown of trust within an administration that’s already been through the ringer.
If you’ve been watching the health policy space, this feels like a long time coming. Makary was supposed to be the "Make America Healthy Again" darling. He was the Johns Hopkins surgeon who talked straight, questioned the COVID status quo, and leaned into the idea that the FDA needed a massive shake-up. But you can only bite the hand that feeds you so many times before the hand pulls away.
The Breaking Point On Abortion Pills
The biggest wedge here isn’t actually about vaccines or "big pharma," though those are factors. The real heat is coming from the anti-abortion wing of the Republican base. They’re furious. They expected Makary to gut access to mifepristone—the abortion pill—but instead, the agency actually allowed a new generic version to hit the market.
Anti-abortion groups like Susan B. Anthony Pro-Life America didn't hold back. They basically called for his head earlier this week. For a president heading into the 2026 midterms, keeping that base happy is everything. Makary’s "methodological purity" (as some call it) didn't leave room for the political wins the White House needed. You can't claim to be a disruptor then follow the standard regulatory playbook on the issues that fire up the voters.
Chaos In The C-Suite
It’s not just the activists. The pharmaceutical industry is in a full-blown revolt. Usually, drugmakers want a predictable FDA. Under Makary, they’ve gotten the opposite.
During his 14 months, the agency has been a black hole for several high-profile drugs. We’re talking about treatments for melanoma (RP1) and Duchenne muscular dystrophy (Deramiocel) that were expected to sail through. Instead, the FDA moved the goalposts. Investors hate uncertainty. When you start rejecting drugs that have already hit their trial endpoints, you lose the room.
Then there’s the Vinay Prasad situation. Makary brought in Prasad—a guy who’s basically a lightning rod for controversy—to run the vaccine wing. They bypassed expert panels. They announced major policy changes in medical journals and on TV instead of through official rule-making. It was messy. Prasad left in April after a public brawl with drug giants, and it seems he took Makary’s political cover with him.
Vaping And The Great Nicotine Debate
Don't forget the vapes. Trump has been very vocal about "making vaping great again," but Makary was seen as dragging his feet on authorizing flavored nicotine products.
Just a few days ago, the FDA finally approved some fruit-flavored e-cigarettes for adults. It looked like a desperate attempt to stay in the President’s good graces. But it was too little, too late. Sources say Trump was already convinced that Makary wasn't "moving fast enough." It’s a classic Trump move: if you aren't 100% on board with the brand, you're out.
Who Is Running The Show Now
If Makary is actually "done," as some officials are saying, the leadership vacuum at the Department of Health and Human Services (HHS) is going to be massive. We don't have a permanent CDC director right now. We don't have a Surgeon General. If the FDA goes into "acting" mode under Deputy Commissioner Kyle Diamantas, the whole agency stalls.
For the biotech sector, a change might actually be a relief. Analysts are already saying that removing Makary could bring "consistency" back to the table. Basically, they'd rather have a predictable bureaucrat than a "visionary" who changes the rules every Tuesday.
If you're an investor or just someone following the "MAHA" movement, pay attention to who gets the nod next. If it's another disruptor, expect more of the same chaos. If it's a corporate-friendly pick, it's a sign that the administration is waving the white flag on radical FDA reform.
Watch the headlines over the next 48 hours. If the formal resignation doesn't drop by Monday, it means Makary is still fighting for his life in the Oval Office. But from where I'm sitting, the writing is on the wall.
Check your portfolio if you hold biotech. Keep an eye on the HHS vacancy list. This isn't just about one doctor; it's about whether the "health revolution" can actually survive the reality of Washington politics.
